Table 2.

Percentage (%) of Lesions Progressing to Cavitation According to Surface Type and ICDAS and Activity Scores at Baseline

Baseline ICDAS	Active Lesion	Surface Type	Total Number of Surfaces	Ever Progressed, N (%)	Progressed within First 2 yrs, N (%)
Unerupted	No	B	4,243	12 (0%)	3 (0%)
0	No	B	7,905	105 (1%)	49 (1%)
1	No	B	84	6 (7%)	3 (4%)
1	Yes	B	361	24 (7%)	8 (2%)
2	No	B	25	1 (4%)	1 (4%)
2	Yes	B	267	41 (15%)	15 (6%)
3	No	B	2	0 (0%)	0 (0%)
3	Yes	B	8	2 (25%)	1 (13%)
Unerupted	No	L	4,246	11 (0%)	2 (0%)
0	No	L	8,305	138 (2%)	54 (1%)
1	No	L	56	3 (5%)	1 (2%)
1	Yes	L	150	19 (13%)	6 (4%)
2	No	L	13	0 (0%)	0 (0%)
2	Yes	L	151	21 (14%)	5 (3%)
3	Yes	L	4	3 (75%)	2 (50%)
4	Yes	L	3	2 (67%)	1 (33%)
Unerupted	No	D	4,245	17 (0%)	4 (0%)
0	No	D	8,344	196 (2%)	80 (1%)
1	No	D	2	0 (0%)	0 (0%)
1	Yes	D	213	33 (15%)	15 (7%)
2	Yes	D	76	26 (34%)	11 (14%)
3	Yes	D	8	2 (25%)	1 (13%)
4	Yes	D	22	15 (68%)	10 (45%)
Unerupted	No	M	4,245	14 (0%)	4 (0%)
0	No	M	7,916	174 (2%)	72 (1%)
1	No	M	21	2 (10%)	0 (0%)
1	Yes	M	459	72 (16%)	20 (4%)
2	No	M	47	6 (13%)	4 (9%)
2	Yes	M	125	49 (39%)	22 (18%)
3	No	M	1	0 (0%)	0 (0%)
3	Yes	M	18	11 (61%)	7 (39%)
4	Yes	M	36	29 (81%)	22 (61%)
Unerupted	No	BP	999	42 (4%)	7 (1%)
0	No	BP	1,312	113 (9%)	61 (5%)
1	No	BP	30	8 (27%)	3 (10%)
1	Yes	BP	49	18 (37%)	9 (18%)
2	No	BP	5	2 (40%)	2 (40%)
2	Yes	BP	64	31 (48%)	19 (30%)
3	Yes	BP	14	12 (86%)	8 (57%)
4	Yes	BP	5	5 (100%)	4 (80%)
Unerupted	No	LG	972	9 (1%)	5 (1%)
0	No	LG	1,269	74 (6%)	38 (3%)
1	No	LG	87	24 (28%)	13 (15%)
1	Yes	LG	76	16 (21%)	6 (8%)
2	No	LG	8	2 (25%)	1 (13%)
2	Yes	LG	55	19 (35%)	11 (20%)
3	Yes	LG	9	4 (44%)	4 (44%)
4	Yes	LG	4	0 (0%)	0 (0%)
Unerupted	No	O	2,836	202 (7%)	46 (2%)
0	No	O	2,498	314 (13%)	159 (6%)
1	No	O	149	55 (37%)	27 (18%)
1	Yes	O	306	104 (34%)	58 (19%)
2	No	O	27	11 (41%)	9 (33%)
2	Yes	O	301	166 (55%)	99 (33%)
3	No	O	1	1 (100%)	1 (100%)
3	Yes	O	94	73 (78%)	49 (52%)
4	Yes	O	46	25 (54%)	17 (37%)